A Phase I Study of the Hu3F8 Antibody plus GM-CSF in Patients with Relapsed/Refractory Neuroblastoma

Protocol
12-230
Full Title
Phase I Study of Combination Therapy of Antibody Hu3F8 with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients with Relapsed/Refractory High-Risk Neuroblastoma
Phase
I
Disease Status
Relapsed/Refractory
Purpose

3F8 is an antibody that attaches to neuroblastoma cells and helps focus a patient’s own immune system — especially white blood cells — to attack neuroblastoma cells. Conventional 3F8 is made from mouse cells. Humanized 3F8 (Hu3F8) is made to be more like the human immune system than a mouse’s immune system, so it may be associated with fewer side effects in patients than standard mouse-derived 3F8.

GM-CSF is a protein that increases the number of white blood cells and may make them better able to kill cancer cells. GM-CSF has been shown to make mouse 3F8 more effective against neuroblastoma, and it is believed to make Hu3F8 more effective as well. The purpose of this study is to find the highest dose of Hu3F8 that can be given safely with GM-CSF in patients with neuroblastoma that has persisted or returned despite prior treatment.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have neuroblastoma that has persisted or returned despite prior treatment.
  • This study is open to patients over age 1 year. At least 3 weeks must have passed since completion of prior chemotherapy or immunotherapy and entry into the study.
  • Prior treatment with mouse or human 3F8 is permitted.

For more information about this study and to inquire about eligibility, please contact Dr. Brian Kushner at 212-639-6793.

Disease(s)
Neuroblastoma
Locations
Related Diseases